![David Moore](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Moore
Direktor/Vorstandsmitglied bei
CORIUM INTERNATIONAL INC
Vermögen: 304 668 $ am 31.08.2026
Profil
David S.
Moore is currently Chairman at Novasenta, Inc. since 2023.
Mr. Moore is Director at Corium LLC (Massachusetts) and Tremeau Pharmaceuticals, Inc. Mr. Moore is Independent Director at Corvus Pharmaceuticals, Inc. starting in 2025.
Mr. Moore is Partner at Gurnet Point Capital LLC since 2020.
Formerly, Mr. Moore was Chief Executive Officer at Roivant Sciences, Inc. from 2019 to 2020.
Mr. Moore was Independent Director at Sirona Biochem Corp.
from 2014 to 2017.
Mr. Moore was Director at Alladapt Immunotherapeutics, Inc. Mr. Moore was President & Chief Commercial Officer at Cempra, Inc. from 2016 to 2019.
Mr. Moore was Chief Business Officer at OCERA Therapeutics LLC in 2013.
Mr. Moore was Chief Business Officer at Tranzyme Pharma, Inc. (Canada) from 2012 to 2013.
Mr. Moore was Senior Vice President-US Commercial at Novo Nordisk, Inc. Education includes undergraduate studies at Thomas Jefferson University and Towson University, and an MBA from Lehigh University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.06.2026 | 21’700 ( 0.03% ) | 304 668 $ | 31.08.2026 |
Aktive Positionen von David Moore
| Unternehmen | Position | Beginn |
|---|---|---|
| CORIUM INTERNATIONAL INC | Direktor/Vorstandsmitglied | - |
| CORVUS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 02.10.2025 |
Gurnet Point Capital LLC
 Gurnet Point Capital LLC Investment ManagersFinance Gurnet Point Capital invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technologies sector. It provides financing for buyout stage capital requirements. It also acquires majority stake and control positions. | Private Equity Investor | 01.03.2020 |
Tremeau Pharmaceuticals, Inc.
 Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and delivers non-opioid pain therapies for people | Direktor/Vorstandsmitglied | - |
Novasenta, Inc.
 Novasenta, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for immune-mediated diseases and cancer | Vorsitzender | 01.01.2023 |
Ehemalige bekannte Positionen von David Moore
| Unternehmen | Position | Ende |
|---|---|---|
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Vorstandsvorsitzender | 01.03.2020 |
Cempra, Inc.
 Cempra, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company with interest in manufacturing pharmaceutical products | Präsident | 01.05.2019 |
| SIRONA BIOCHEM CORP. | Direktor/Vorstandsmitglied | 27.10.2017 |
| OCERA THERAPEUTICS INC | Corporate Officer/Principal | 01.07.2013 |
| ░░░░░░░░ ░░░░░░░ ░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von David Moore
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
62
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
Thomas Jefferson University
 Thomas Jefferson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sirona Biochem Corp.
 Sirona Biochem Corp. Pharmaceuticals: MajorHealth Technology Develops cosmetic and pharmaceutical active ingredients | Health Technology |
Cempra, Inc.
Cempra, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company with interest in manufacturing pharmaceutical products | Health Technology |
Corvus Pharmaceuticals, Inc.
 Corvus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides anticancer immuno-oncology drugs | Health Technology |
OCERA Therapeutics LLC
 OCERA Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Lehigh University
 Lehigh University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Towson University
 Towson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Corium International, Inc.
 Corium International, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of novel neuroscience therapies | Health Technology |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Develops biological medicines | Health Technology |
Tranzyme Pharma, Inc. (Canada) | |
Gurnet Point Capital LLC
Gurnet Point Capital LLC Investment ManagersFinance Gurnet Point Capital invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technologies sector. It provides financing for buyout stage capital requirements. It also acquires majority stake and control positions. | Finance |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Tremeau Pharmaceuticals, Inc.
Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and delivers non-opioid pain therapies for people | Health Technology |
Alladapt Immunotherapeutics, Inc.
 Alladapt Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics targeting food allergy | Health Technology |
Novasenta, Inc.
Novasenta, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for immune-mediated diseases and cancer | Health Technology |
